Cerecor, a publicly traded biopharmaceutical company developing treatments for orphan disorders, is planning to relocate from Baltimore city to Rockville, Md.
According to documents filed with the U.S. Securities and Exchange Commission, the company recently signed a lease for a new 6,000 sq. ft. headquarters in Rockville.
A Cerecor spokesperson said the company plans to move around the end of the year, when its current lease expires at Inner Harbor’s 400 E. Pratt St. Five employees, most of whom already live around Montgomery County, are expected to relocate. The new office will have room for nearly 20 employees. The company currently employs close to 50 people, with many based outside of Maryland.
The company has made a series of moves in 2018. In the spring, Cerecor appointed Peter Greenleaf as CEO, who formerly served as president of Gaithersburg-based MedImmune and CEO of Rockville-based Sucampo Pharmaceuticals. Greenleaf told the Baltimore Business Journal at the time that the company wants to be a leader in pediatric healthcare. Cerecor has also made a series of acquisitions toward bolstering its pipeline in that area. The most recent came this week with a deal for New York–based Ichorion Therapeutics that could be worth up to $26.6 million in stock, plus milestones.
With the move, Cerecor will be close to a number of other publicly-traded Maryland biotech companies.
A look down East Pratt Street along Baltimore's Inner Harbor.
(Photo by Stephen Babcock)
Companies: Cerecor Inc.
